治疗转移性小细胞肺癌新药:lurbinectedin

A new drug in treatment of metastatic small cell lung cancer: lurbinectedin

lurbinectedin是一种烷基化抗肿瘤药物,可抑制DNA上蛋白质编码基因的主动转录,导致细胞周期紊乱,诱导细胞死亡。该药于2020年6月15日被美国食品和药物管理局批准上市,用于治疗在铂类药物化疗期间或之后出现疾病进展的转移性小细胞肺癌成人患者。临床试验表明,lurbinectedin对转移性小细胞肺癌具有良好的疗效,常见不良反应为骨髓抑制、恶心和呕吐等,患者耐受性较好。

Lurbinectedin is an alkylated antitumor drug which can inhibit the active transcription of protein-coding genes on DNA, disrupt the cell cycle and induce cell death. Lurbinectedin was approved for the treatment of adult patients with metastatic small cell lung cancer(SCLC) with disease progression on or after platinum-based chemotherapy by the U.S. Food and Drug Administration on June 15, 2020. Clinical trials have shown that lurbinectedin has a good effect on metastatic SCLC. The common adverse reactions are bone marrow suppression, nausea and vomiting, etc. The patient is well tolerated.